FDA approves first Alzheimer's therapy shown to slow cognitive decline
The first Alzheimer’s drug proven to moderately slow the course of the disease gained full approval from the Food and Drug Administration (FDA) on Thursday. The FDA said the approval was based on clinical trial data that showed Leqembi slows cognitive decline by about 27 percent compared to a placebo among Alzheimer’s patients who are…